Ourania Kostopoulous team

Publikationer

Alla gruppmedlemmars publikationer

• Article: BIOMEDICINE & PHARMACOTHERAPY. 2024;180:117500

  Enhancing targeted therapy by combining PI3K and AKT inhibitors with or without cisplatin or vincristine in medulloblastoma cell lines in vitro

  Lukoseviciute M; Need E; Birgersson M; Dalianis T; Kostopoulou ON
• Article: BIOMEDICINE & PHARMACOTHERAPY. 2024;177:116993

  Combined targeted therapy with PI3K and CDK4/6, or FGFR inhibitors show synergistic effects in a neuroblastoma spheroid culture model

  Lukoseviciute M; Need E; Holzhauser S; Dalianis T; Kostopoulou ON
• Article: ANTICANCER RESEARCH. 2024;44(5):1863-1876

  Curcumin Alone and Combined With PI3K Inhibitors Elicits Positive Effects on Oropharyngeal Cancer Cell Lines Regardless of HPV Status

  Lukoceviciute M; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
• Article: ORAL ONCOLOGY. 2024;151:106749

  Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival

  Zupancic M; Kostopoulou ON; Holzhauser S; Lukoseviciute M; Jylha C; Marklund L; Nasman A; Sivars L; Dalianis T
• Review: ANTICANCER RESEARCH. 2023;43(9):3829-3839

  New Approaches Towards Targeted Therapy for Childhood Neuroblastoma

  Dalianis T; Lukoseviciute M; Holzhauser S; Kostopoulou ON
• Article: ONCOLOGY REPORTS. 2023;50(3):166

  Efficacy of combined targeted therapy with PI3K and CDK4/6 or PARP and WEE1 inhibitors in neuroblastoma cell lines

  Lukoseviciute M; Holzhauser S; Pappa E; Mandal T; Dalianis T; Kostopoulou ON
• Article: ONCOLOGY REPORTS. 2023;49(6):125

  Combination of PARP and WEE1 inhibitors in vitro: Potential for use in the treatment of SHH medulloblastoma

  Lukoseviciute M; Theodosopoulou A; Holzhauser S; Dalianis T; Kostopoulou ON
• Article: CANCERS. 2023;15(7):1954

  High Levels of FGF11 Correlate with Poor Survival in Patients with Human Papillomavirus (HPV)-Positive Oropharyngeal Squamous Cell Carcinoma

  de Flon CH; Haeggblom L; Holzhauser S; Kostopoulou ON; Zupancic M; Dalianis T; Munck-Wikland E; Marklund L; Nasman A
• Article: CANCERS. 2022;15(1):93

  Targeted Therapy with PI3K, PARP, and WEE1 Inhibitors and Radiotherapy in HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy while Effects with APR-246 Are Limited

  Byskata K; Lukoseviciute M; Tuti F; Zupancic M; Kostopoulou ON; Holzhauser S; Dalianis T
• Article: VIRUSES-BASEL. 2022;14(7):1372

  Targeted Therapy of HPV Positive and Negative Tonsillar Squamous Cell Carcinoma Cell Lines Reveals Synergy between CDK4/6, PI3K and Sometimes FGFR Inhibitors, but Rarely between PARP and WEE1 Inhibitors

  Kostopoulou ON; Zupancic M; Pont M; Papin E; Lukoseviciute M; Mikelarena BA; Holzhauser S; Dalianis T
• Article: MICROORGANISMS. 2021;9(6):1137

  Human Cytomegalovirus Reduces Endothelin-1 Expression in Both Endothelial and Vascular Smooth Muscle Cells

  Yaiw K-C; Mohammad A-A; Taher C; Cui HL; Costa H; Kostopoulou ON; Jung M; Assinger A; Wilhelmi V; Yang J; Straat K; Rahbar A; Pernow J; Soderberg-Naucler C
• Review: VIRUSES-BASEL. 2021;13(5):910

  Prognostic Markers and Driver Genes and Options for Targeted Therapy in Human-Papillomavirus-Positive Tonsillar and Base-of-Tongue Squamous Cell Carcinoma

  Nasman A; Holzhauser S; Kostopoulou ON; Zupancic M; Ahrlund-Richter A; Du J; Dalianis T
• Article: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2021;22(7):3664

  Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines

  Jonsson LO; Sahi M; Lopez-Lorenzo X; Keller FL; Kostopoulou ON; Herold N; Ahrlund-Richter L; Fard SS
• Review: ANTICANCER RESEARCH. 2021;41(4):1715-1726

  New Approaches in Targeted Therapy for Medulloblastoma in Children

  Maier H; Dalianis T; Kostopoulou ON
• Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2021;58(2):211-225

  Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines

  Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickstrom M; Kostopoulou ON; Dalianis T
• Article: FRONTIERS IN ONCOLOGY. 2021;11:640490

  Targeted Therapy With PI3K and FGFR Inhibitors on Human Papillomavirus Positive and Negative Tonsillar and Base of Tongue Cancer Lines With and Without Corresponding Mutations

  Holzhauser S; Wild N; Zupancic M; Ursu RG; Bersani C; Nasman A; Kostopoulou ON; Dalianis T
• Article: FRONTIERS IN ONCOLOGY. 2021;11:748657

  Targeting PI3K, FGFR, CDK4/6 Signaling Pathways Together With Cytostatics and Radiotherapy in Two Medulloblastoma Cell Lines

  Lukoseviciute M; Maier H; Poulou-Sidiropoulou E; Rosendahl E; Holzhauser S; Dalianis T; Kostopoulou ON
• Article: BIOLOGY-BASEL. 2020;9(3):E44-44

  Human Cytomegalovirus Infection Induces High Expression of Prolactin and Prolactin Receptors in Ovarian Cancer

  Rahbar A; AlKharusi A; Costa H; Pantalone MR; Kostopoulou ON; Cui HL; Carlsson J; Radestad AF; Soderberg-Naucler C; Norstedt G
• Article: ANTICANCER RESEARCH. 2020;40(1):53-66

  Targeting Fibroblast Growth Factor Receptor (FGFR) and Phosphoinositide 3-kinase (PI3K) Signaling Pathways in Medulloblastoma Cell Lines

  Holzhauser S; Lukoseviciute M; Andonova T; Ursu RG; Dalianis T; Wickstrom M; Kostopoulou ON
• Article: ONCOLOGY LETTERS. 2019;18(6):6249-6260

  In vitro antitumor effects of FGFR and PI3K inhibitors on human papillomavirus positive and negative tonsillar and base of tongue cancer cell lines

  Holzhauser S; Kostopoulou ON; Ohmayer A; Lange BKA; Ramqvist T; Andonova T; Bersani C; Wickstrom M; Dalianis T
• Article: INTERNATIONAL JOURNAL OF ONCOLOGY. 2019;55(6):1372-1384

  Analyses of FGFR3 and PIK3CA mutations in neuroblastomas and the effects of the corresponding inhibitors on neuroblastoma cell lines

  Kostopoulou ON; Holzhauser S; Lange BKA; Ohmayer A; Andonova T; Bersani C; Wickstrom M; Dalianis T
• Article: TRANSLATIONAL ONCOLOGY. 2018;11(6):1292-1300

  Impact of Human Cytomegalovirus Infection and its Immune Response on Survival of Patients with Ovarian Cancer

  Radestad AF; Estekizadeh A; Cui HL; Kostopoulou ON; Davoudi B; Hirschberg AL; Carlson J; Rahbar A; Soderberg-Naucler C
• Article: INTERNATIONAL JOURNAL OF CANCER. 2018;142(6):1266-1276

  Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance

  Kostopoulou ON; Mohammad A-A; Bartek JJ; Winter J; Jung M; Stragliotto G; Soderberg-Naucler C; Landazuri N
• Article: ONCOTARGET. 2017;8(57):96536-96552

  Human cytomegalovirus and Herpes Simplex type I virus can engage RNA polymerase I for transcription of immediate early genes

  Kostopoulou ON; Wilhelmi V; Raiss S; Ananthaseshan S; Lindstrom MS; Bartek J; Soderberg-Naucler C
• Article: ONCOTARGET. 2016;7(30):47221-47231

  Human cytomegalovirus may promote tumour progression by upregulating arginase-2

  Costa H; Xu X; Overbeek G; Vasaikar S; Patro CPK; Kostopoulou ON; Jung M; Shafi G; Ananthaseshan S; Tsipras G; Davoudi B; Mohammad A-A; Lam H; Straat K; Wilhelmi V; Shang M; Tegner J; Tong JC; Wong KT; Soderberg-Naucler C; Yaiw K-C
• Article: JOURNAL OF GENERAL VIROLOGY. 2015;96(12):3598-3612

  Direct infection of primary endothelial cells with human cytomegalovirus prevents angiogenesis and migration

  Gustafsson RKL; Jeffery HC; Yaiw K-C; Wilhelmi V; Kostopoulou ON; Davoudi B; Rahbar A; Benard M; Renne T; Soderberg-Naucler C; Butler LM
• Article: BIOORGANIC & MEDICINAL CHEMISTRY. 2015;23(13):3163-3174

  Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.

  Magoulas GE; Kostopoulou ON; Garnelis T; Athanassopoulos CM; Kournoutou GG; Leotsinidis M; Dinos GP; Papaioannou D; Kalpaxis DL
• Article: JOURNAL OF ENDOUROLOGY. 2015;29(5):580-589

  Evaluation of the distribution of Paclitaxel by immunohistochemistry and nuclear magnetic resonance spectroscopy after the application of a drug-eluting balloon in the porcine ureter.

  Liourdi D; Kallidonis P; Kyriazis I; Tsamandas A; Karnabatidis D; Kitrou P; Spyroulias GA; Kostopoulou ON; Marousis K; Kalpaxis DL; Goumenos DS; Liatsikos E
• Article: PLOS ONE. 2015;10(8):e0134526

  Synthesis and Evaluation of Chloramphenicol Homodimers: Molecular Target, Antimicrobial Activity, and Toxicity against Human Cells

  Kostopoulou ON; Magoulas GE; Papadopoulos GE; Mouzaki A; Dinos GP; Papaioannou D; Kalpaxis DL
• Article: NUCLEIC ACIDS RESEARCH. 2014;42(13):8621-8634

  Conjugation with polyamines enhances the antibacterial and anticancer activity of chloramphenicol.

  Kostopoulou ON; Kouvela EC; Magoulas GE; Garnelis T; Panagoulias I; Rodi M; Papadopoulos G; Mouzaki A; Dinos GP; Papaioannou D; Kalpaxis DL
• Article: PHARMAZIE. 2013;68(7):616-621

  Clindamycin binding to ribosomes revisited: foot printing and computational detection of two binding sites within the peptidyl transferase center.

  Kostopoulou ON; Papadopoulos G; Kouvela EC; Kalpaxis DL
• Article: NUCLEIC ACIDS RESEARCH. 2012;40(11):5078-5087

  Investigating the entire course of telithromycin binding to Escherichia coli ribosomes.

  Kostopoulou ON; Petropoulos AD; Dinos GP; Choli-Papadopoulou T; Kalpaxis DL
• Journal article: OPEN ENZYME INHIBITION JOURNAL. 2011;4(1):1-10

  Insights into the Chloramphenicol Inhibition Effect on Peptidyl Transferase Activity, Using Two New Analogs of the Drug

  Kostopoulou ON
• Article: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. 2010;35(3):235-239

  Dissecting the ribosomal inhibition mechanism of a new ketolide carrying an alkyl-aryl group at C-13 of its lactone ring.

  Krokidis MG; Kostopoulou ON; Kalpaxis DL; Dinos GP
• Visa fler

Medarbetare och kontakt

Gruppledare

• 

  Ourania Kostopoulou

  Senior Forskningsspecialist | Adjunkt | Docent

  E-postadress ourania.kostopoulou@ki.se

Alla medarbetare i gruppen

• 

  Ourania Kostopoulou

  Senior Forskningsspecialist | Adjunkt | Docent

  E-postadress ourania.kostopoulou@ki.se
• Monika Lukoseviciute

  Doktorand

  E-postadress monika.lukoseviciute@ki.se